Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2018
Price :
$35
*
At a glance
- Drugs Hydrogen peroxide (Primary)
- Indications Seborrhoeic keratosis
- Focus Registrational; Therapeutic Use
- Sponsors Aclaris Therapeutics
- 01 Jun 2018 Results of two identical studies (NCT02667236 and NCT02667275) assessing the safety and efficacy of hydrogen peroxide topical solution, 40%, published in the Journal of the American Academy of Dermatology
- 16 May 2018 According to an Aclaris Therapeutics media release, data will be presented at the International Investigative Dermatology (IID) 2018 Meeting.
- 15 Dec 2017 According to an Aclaris Therapeutics media release, the U.S. Food and Drug Administration (FDA) has approved ESKATA (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. Approval is based on two pivotal Phase 3 trials.